Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Press Releases
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
1917.00 JPY   +0.63%
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezolinetant
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Application for Fezolinetant
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société ASTELLAS PHARMA INC.
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezo..
AQ
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/09Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
AQ
07/31Astellas Pharma : Financial Results (Q1/FY2022)
PU
07/31Astellas Pharma : Presentation Material for Information Meeting (Q1/FY2022)
PU
07/31Astellas Pharma : Supplementary Documents (Q1/FY2022)
PU
07/27Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
AQ
07/26Astellas Pharma : and Seagen Announce Positive Topline Results For PADCEV with KEYTRUDA as..
PU
06/27Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Nove..
AQ
06/27Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late..
AQ
06/23We Published A Story : “Astellas' Path to Sustainability Vol.1: A New Materiality Ma..
PU
06/23Astellas' Path To Sustainability Vol : A New Materiality Matrix as a Compass to Direct our..
PU
05/25Astellas Pharma : Posted Notice of Convocation of the 17th Term Annual Shareholders Meetin..
PU
05/25Astellas Pharma : Notice of Convocation of the 17th Term Annual Shareholders Meetingᦀ..
PU
05/19Astellas Pharma : Confirms Unfavorable District Court Decision in LEXISCAN® 0.4mg/mL U.S. ..
PU
04/27Astellas Pharma : Changes of Representative Director and Directors
PU
04/26Astellas Pharma : Financial Results (FY2021)
PU
04/26Astellas Pharma : Supplementary Documents (FY2021)
PU
04/26Astellas Pharma : Presentation Material for Information Meeting (FY2021)
PU
04/26Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio..
AQ
04/21Astellas Pharma : Notice Regarding Impairment Loss for Products under Development
PU
04/13Astellas Pharma : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv..
PU
04/04We Published A New Sustainability Se : “Developing a sustainable society by leveragi..
PU
03/31Astellas Pharma : We published a Drug Research page.
PU
03/15Astellas Pharma : Initiatives for Gene Therapy(2,933KB)
PU
03/14Astellas Pharma : Reinvigorating the immune system to find new ways to cure cancer
PU
03/13We Published A Story : “Reinvigorating the immune system to find new ways to cure ca..
PU
03/10Astellas Pharma : Meeting Script(8,030KB)
PU
03/09Astellas Pharma : Announces Completion of Acquisition of Own Shares, and Cancellation of T..
PU
03/09Astellas Pharma : Update on ukraine
PU
03/08Astellas Pharma : Presentation Material for R&D Meeting
PU
03/08Astellas Pharma : Updated “R&D meeting” Section
PU
03/08Astellas Pharma : Initiatives for Gene Therapy(2,929KB)
PU
03/06Astellas Pharma : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolin..
PU
03/01We Published A Story : “Astellas' VALUE powered by people—New Challenge of HR...
PU
03/01Astellas Pharma : ' VALUE powered by people — New Challenge of HR
PU
03/01Astellas Pharma : Meeting Script(4,467KB)
PU
02/28Astellas Pharma : Announces Status of Acquisition of Own Shares
PU
02/28Astellas Pharma : and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortuma..
PU
02/28Astellas Pharma : Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent..
PU
02/27Astellas Pharma : Updated “Sustainability Meeting” Section
PU
02/27Astellas Pharma : Aiming to Enhance the Sustainability of Society and Astellas' Corporate ..
PU
02/27Astellas Pharma : Presentation Material for Sustainability Meeting
PU
02/17Astellas Pharma : New research organization structure(1,245kb)
PU
02/14Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Pa..
BU
02/08Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with L..
AQ
02/07Astellas Pharma : Announces Management Structure
PU
02/03Astellas Pharma : Initiates Charitable Donations to Support Four Organizations Focused on ..
PU
02/01Astellas Pharma : Announces Acquisition of Own Shares and Cancellation of Treasury Stock
PU
02/01Astellas Pharma : Financial Results (Q3/FY2021)
PU
02/01Astellas Pharma : Supplementary Documents (Q3/FY2021)
PU
02/01Astellas Pharma : Presentation Material for Information Meeting (Q3/FY2021)
PU
01/24Astellas Pharma : Meeting Script(3,989KB)
PU
01/20Astellas Pharma : We posted the presentation material for media briefing on Digital Transf..
PU
01/20Astellas Pharma : Digital Transformation of Astellas Pharma(3,351KB)
PU
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
AQ
2021Astellas Pharma : and Seagen Receive Positive CHMP Opinion for PADCEV (enfortumab vedotin)..
PU
2021Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin..
BU
2021Astellas Pharma : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
2021Guard Therapeutics appoints Michael Reusch as Chief Medical Officer
AQ
2021Astellas and MBC BioLabs Announce Future Innovator Prize Winners, Helping Biotech Start..
AQ
2021Astellas Pharma : Changes its Corporate Website Structure
PU
2021Astellas Applied for Selection of 'Prime Market' segment of the Tokyo Stock Exchange
AQ
2021Astellas Pharma : New Research Organization Structure
PU
2021Astellas Pharma : Presentation Material for R&D Meeting
PU
2021Astellas Pharma : Corporate Governance Report
PU
2021Astellas Pharma : Applied for Selection of “Prime Market”segment of the Tokyo ..
PU
2021Astellas Pharma : Applied for Selection of “Prime Market” segment of the Tokyo..
PU
2021Astellas Pharma : Corporate Covernance Report
PU
2021Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
2021Astellas Pharma : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
2021We Published A Story : “Patient centricity at Astellas—all about action.&rdquo..
PU
2021Astellas Pharma : Patient centricity at Astellas—all about action
PU
1  2  3  4  5  6  7  8  9Next
Upcoming event on ASTELLAS PHARMA INC.